期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
卷 116, 期 -, 页码 1260-1267出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijbiomac.2018.05.079
关键词
Temozolomide; Chitosan; Cytotoxicity study; Brain distribution; Nasal histopathology
资金
- IGIB, New Delhi, India
The present study was designed to develop and optimize Temozolomide nano lipid chitosan hydrogel formulations (TMZNLCHG) to target the brain through nasal route. The formulation was developed using chitosan as a gelling agent and Vit E: gelucire 44/14 blend as lipid. The formulations were evaluated for particle size, encapsulation efficiency (%EE), drug loading (DL), morphology, drug release, nasal diffusion, cell line study, and histopathology study. The particle size, PDI, %EE, %DL, and drug release were found to be 134 nm, 0.177, 88.45% +/- 4.45%, 9.12% +/- 0.78%, and 84.23% +/- 2.78%, respectively. The enhancement ratio was more than two folds higher than TMZCHG formulation (control) suggesting the superiority of chitosan with lipid as permeability enhancer. The microscopic image of lyophilized TMZNLCHGopt displayed the spherical and rough surface morphology. IC50 was found to be 334 mu g/ml for TMZNLCHGopt and was 160 mu g/ml for pure TMZ. Further, No structural damage was observed with TMZNLCHGopt treated nasal mucosa upon histopathological examination. Overall, the present study produces encouraging findings in the formulation of a non-invasive intranasal route for brain targeting as an alternate to other route for TMZ. (C) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据